Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

Award Number: R44AI114331
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2014
PERIOD OF PERFORMANCE END DATE: 08/31/2019

Group Awards By:

View Award Description

Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine - Abstract There is a growing consensus that protection against HIV infection will require BOTH antiviral antibody responses as well as polyfunctional CD4+ and CD8+ T cells with potent lytic activity. To stimulate the breadth, potency, and rate of response required, Profectus Biosciences intends to utilize its platform technologies based on DNA vaccines combined with genetic adjuvants. As a step in that direction, a phase 1 clinical trial, HVTN- 080, showed that electroporation in combination with our IL-12 adjuvant can double the CD4+ and CD8+ T cell response rate in vaccinees over electroporation alone1. Even with this success, we recognize that a truly effective HIV vaccine will require a regimen that can consistently provide high magnitude, long-lived responses at rates >95% with as few booster immunizations as possible. We believe that adjuvants are a key to developing such a vaccine. Under our phase I SBIRs, we identified a new class of genetic adjuvants that exploit the RIG-I signaling cascades and trigger potent anti-viral innate immune responses. These innate responses integrate with TLR evoked innate responses and DAMPs/alarmins to evoke potent anti-viral adaptive immune responses. Also under phase I, we found that the adjuvants attenuated vaccine antigen expression by negatively impacting the promoter. We have now developed an improved promoter to drive our vaccine antigen and adjuvant expression that is not attenuated by these adjuvants. Under this phase II SBIR, we intend to identify an optimal combination of DNA adjuvants using a macaque model. Upon completion of phase II, we expect to have identified a lead adjuvant combination worthy of testing with our HIV vaccine in phase I human trials. 2


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $1,062 )
2022	2019	ORLANCE, INC.	1124 COLUMBIA ST STE 300	SEATTLE	WA	98104	KING	USA	Allergy and Infectious Diseases Research	000	3	4/14/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2018	PROFECTUS BIOSCIENCES, INC.	401 N MIDDLETOWN RD # 205	PEARL RIVER	NY	10965	ROCKLAND	USA	Allergy and Infectious Diseases Research	001	2	9/23/2022	COMPETING CONTINUATION	$1,062
														Subtotal = $1,062

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	ORLANCE, INC.	4000 15TH AVE NE	SEATTLE	WA	98195	KING	USA	Allergy and Infectious Diseases Research	000	3	8/9/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	ORLANCE, INC.	4000 15TH AVE NE	SEATTLE	WA	98195	KING	USA	Allergy and Infectious Diseases Research	001	3	12/19/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$209,092
2020	2018	PROFECTUS BIOSCIENCES, INC.	401 N MIDDLETOWN RD # 205	PEARL RIVER	NY	10965	ROCKLAND	USA	Allergy and Infectious Diseases Research	000	2	12/19/2019	COMPETING CONTINUATION	-$209,092
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $569,505 )
2019	2019	ORLANCE, INC.	4000 15TH AVE NE	SEATTLE	WA	98195	KING	USA	Allergy and Infectious Diseases Research	001	3	8/23/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$569,505
2019	2018	PROFECTUS BIOSCIENCES, INC.	6411 BECKLEY ST STE 201	BALTIMORE	MD	21224	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	2	8/23/2019	COMPETING CONTINUATION	$0
														Subtotal = $569,505

Issue Date FY: 2018 ( Subtotal = $993,161 )
2018	2018	PROFECTUS BIOSCIENCES, INC.	6411 BECKLEY ST STE 201	BALTIMORE	MD	21224	BALTIMORE CITY	USA	Allergy and Infectious Diseases Research	000	2	8/28/2018	COMPETING CONTINUATION	$993,161
														Subtotal = $993,161

Grand Total All Awards = $1,563,728

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimization of an innate immune stimulating adjuvant for an HIV DNA vaccine

Award Number: R44AI114331

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2014

PERIOD OF PERFORMANCE END DATE: 08/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer